NCT07115472View on ClinicalTrials.gov

Fluoxetine in Refractory Superior Mesenteric Artery Syndrome by Targeting Comorbid Somatic Symptom Disorder

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

December 1, 2024

Study Completion Date

June 1, 2025

Conditions
Superior Mesenteric Artery SyndromeSomatic Symptom Disorder (DSM-5)
Interventions
DRUG

Fluoxetine

Refractory SMAS patients with SSD received oral fluoxetine treatment, initiated at 20 mg/day and increased to a maximum of 60 mg/day based on therapeutic response.

Trial Locations (1)

710032

Xijing Hospital, Xi'an

All Listed Sponsors
lead

Xijing Hospital of Digestive Diseases

OTHER

NCT07115472 - Fluoxetine in Refractory Superior Mesenteric Artery Syndrome by Targeting Comorbid Somatic Symptom Disorder | Biotech Hunter | Biotech Hunter